Denali Therapeutics Inc
DNLIHealthcare|Biotechnology|USA
$25.68
-1.53 (-5.62%)
Tangible Book
$5.61
About
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Stock Price
+67.3%(1Y)
Pipeline Summary
25 total trials17
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
Terminated: 2ENROLLING_BY_INVITATION: 1Recruiting: 3Completed: 15Active: 4
Active Trials (7)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
NCT07328451Alzheimer Disease, Early Onset
Phase 1Recruiting
Enrollment: 68 participants
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613Mucopolysaccharidosis II
Phase 2Phase 3Recruiting
Enrollment: 63 participants
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193Parkinson Disease
Phase 2Active
Enrollment: 50 participants
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136Mucopolysaccharidosis Type IIIA
Phase 1Phase 2Active
Enrollment: 20 participants
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
NCT07354724Late-onset Pompe Disease
Phase 1Recruiting
Enrollment: 32 participants
BioScore
5.4/10
Watchlist
Ownership
Recent Insider Trades
Watts Ryan J.SELL
2026-01-0635,198 shares @ $16.5
Schuth Alexander O.SELL
2026-01-0617,218 shares @ $16.5
Ho CaroleSELL
2025-08-133,743 shares @ $13.81
Schuth Alexander O.SELL
2025-08-122,937 shares @ $13.58
Watts Ryan J.SELL
2025-07-09495,282 shares @ $15
Recent News
2026-06-18 13:56:19
2026-06-18 12:30:23
Data last updated: Jul 12, 2026, 07:37 PM